Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, September 2011, Pages: 83

Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Cystic Fibrosis Therapeutics market. The report identifies the key trends shaping and driving the global Cystic Fibrosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cystic Fibrosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Cystic Fibrosis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Cystic Fibrosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Cystic Fibrosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Cystic Fibrosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Cystic Fibrosis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Cystic Fibrosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Cystic Fibrosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Cystic Fibrosis Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 CF Therapeutics: Introduction
2.1 Overview
2.2 Etiology and Pathophysiology
2.3 Epidemiology
2.4 Symptoms
2.5 Diagnosis
2.6 Treatment and Management Pattern
2.7 Report Guidance
3 CF Therapeutics: Market Characterization
3.1 CF Therapeutics Market Size (2005-2010) – Global
3.2 CF Therapeutics Market Forecast (2010-2018) – Global
3.3 CF Therapeutics Market Size (2005-2010): The US
3.4 CF Therapeutics Market Forecast (2010-2018): The US
3.5 CF Therapeutics Market (2005-2010): France
3.6 CF Therapeutics Market Forecast (2010-2018): France
3.7 CF Therapeutics Market (2005-2010): Germany
3.8 CF Therapeutics Market Forecast (2010-2018): Germany
3.9 CF Therapeutics Market (2005-2010): Italy
3.10 CF Therapeutics Market Forecast (2010-2018): Italy
3.11 CF Therapeutics Market (2005-2010): Spain
3.12 CF Therapeutics Market Forecast (2010-2018): Spain
3.13 CF Therapeutics Market (2005-2010): The UK
3.14 CF Therapeutics Market Forecast (2010-2018): The UK
3.15 CF Therapeutics Market (2005-2010): Japan
3.16 CF Therapeutics Market Forecast (2010-2018): Japan
3.17 Drivers and Barriers for the CF Therapeutics Market
3.17.1 Drivers for the CF Therapeutics Market
3.17.2 Barriers for the CF Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 CF Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the CF Therapeutics Market
4.3.1 TOBI (tobramycin Inhalation Solution)
4.3.2 Pulmozyme (dornase alfa)
4.3.3 Creon (pancrelipase capsules)
4.3.4 Cayston (aztreonam for inhalation solution)
4.3.5 Colistimethate sodium (Colistin, Colomycin Injection, Promixin, Coly-Mycin M)
4.4 Key Takeaway
5 CF Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 CF Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 CF Therapeutics – Phase III Pipeline
5.3.2 CF Therapeutics – Phase II Pipeline
5.3.3 CF Therapeutics – Phase I Pipeline
5.3.4 CF Therapeutics – Preclinical Pipeline
5.3.5 CF Therapeutics – Discovery Pipeline
5.4 CF Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 CF Therapeutics – Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs Under Clinical Development
5.7.1 VX-770
5.7.2 Ataluren (PTC-124)
5.7.3 Bronchitol
5.7.4 Arikace (liposomal amikacin for inhalation)
5.7.5 MP-376 (levofloxacin solution for inhalation)
5.7.6 Spiriva (tiotropium bromide)
5.7.7 Bramitob Nebuliser Solution
5.7.8 PARI Tobramycin 100 (inhalation)
5.8 Key Takeaway
6 CF Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (the US, EU5, and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials by Overall Sponsors
6.5 Prominent Sponsors
6.6 Key Companies Participating in Therapeutics Clinical Trials
7 CF Therapeutics: Stategic Assessment
7.1 Key Events Impacting the Future Market
7.2 CF Therapeutics: Implications for Future Market Competition
8 CF Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Vertex Pharmaceuticals Inc.
8.2.2 PTC Therapeutics, Inc:
8.2.3 Mpex Pharmaceuticals, Inc.
8.2.4 Insmed Incorporated
8.2.5 Aradigm Corporation
8.2.6 GlaxoSmithKline plc
8.2.7 Actelion Ltd.
8.2.8 Parion Sciences, Inc
8.2.9 Chiesi Farmaceutici SpA.
9 CF Therapeutics: Licensing and Partnership Deals
10 CF Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Symptoms Associated with CF
Table 2: CF Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 3: CF Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 4: CF Therapeutics Market, the US, Revenue ($m), 2005-2010
Table 5: CF Therapeutics Market, the US, Forecast ($m), 2010-2018
Table 6: CF Therapeutics Market, France, Revenue ($m), 2005-2010
Table 7: CF Therapeutics Market, France, Forecast ($m), 2010-2018
Table 8: CF Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 9: CF Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 10: CF Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 11: CF Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 12: CF Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 13: CF Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 14: CF Therapeutics Market, the UK, Revenue ($m), 2005-2010
Table 15: CF Therapeutics Market, the UK, Forecast ($m), 2010-2018
Table 16: CF Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 17: CF Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 18: CF Therapeutics – Strategic Competitor Assessment, 2011
Table 19: Major Marketed Products Analysis in the CF Therapeutics Market, 2011
Table 20: CF Therapeutics Market – Phase III Pipeline, 2011
Table 21: CF Therapeutics Market – Phase II Pipeline, 2011
Table 22: CF Therapeutics Market – Phase I Clinical Pipeline, 2011
Table 23: CF Therapeutics Market – Preclinical Clinical Pipeline, 2011
Table 24: CF Therapeutics Market – Discovery Clinical Pipeline, 2011
Table 25: Cystic Fibrosis – Most Promising Drugs Under Clinical Development, 2010
Table 26: CF Therapeutics Market, Clinical Trials by Region, 2011
Table 27: CF Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011
Table 28: CF Therapeutics Market, Global, Clinical Trials by Trial Status, 2011
Table 29: CF Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011
Table 30: CF Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011
Table 31: CF Therapeutics Market, Global, Clinical Trials by Lead Sponsors, 2011
Table 32: Pipeline Molecules 2011
Table 33: Pipeline Products 2011
Table 34: Pipeline Product 2011
Table 35: Pipeline Product 2011
Table 36: Pipeline Product 2011
Table 37: Product pipeline 2011
Table 38: Pipeline Products 2011
Table 39: Pipeline Products 2011
Table 40: Pipeline Products 2011
Table 41: Licensing and Partnership Deals

1.2 List of Figures
Figure 1: Inheritance of CF in Next Generation
Figure 2: Comparison Between Classic and Non-Classic Cystic Fibrosis
Figure 3: CFTR Channel Mutation and Regulation of the Chloride Channel
Figure 4: Pathophysiology of CF in the Lungs
Figure 5: CF Manifestation in the Pancreas
Figure 6: Diagnosis Algorithm for CF
Figure 7: Treatment Algorithm for CF
Figure 8: CF Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 9: CF Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 10: CF Therapeutics Market, the US, Revenue ($m), 2005-2010
Figure 11: CF Therapeutics Market, the US, Forecast ($m), 2010-2018
Figure 12: CF Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 13: CF Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 14: CF Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 15: CF Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 16: CF Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 17: CF Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 18: CF Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 19: CF Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 20: CF Therapeutics Market, the UK, Revenue ($m), 2005-2010
Figure 21: CF Therapeutics Market, the UK, Forecast ($m), 2010-2018
Figure 22: CF Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 23: CF Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 24: Opportunity and Unmet Need in the CF Therapeutics Market, 2011
Figure 25: CF Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 26: CF Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011
Figure 27: Technology Trends Analytic Framework for the CF Therapeutics Pipeline, 2011
Figure 28: Technology Trends Analytic Framework for the CF Therapeutics Pipeline, 2011
Figure 29: CF Therapeutics Market – Clinical Trials by Region, 2011
Figure 30: CF Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011
Figure 31: CF Therapeutics Market, Global, Clinical Trials by Trial Status, 2011
Figure 32: CF Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011
Figure 33: CF Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011
Figure 34: CF Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Figure 35: Drivers and Barriers of the CF Therapeutics Market
Figure 36: Implications for Future Market Competition in the CF Therapeutics Market, 2011
Figure 37: CF Therapeutics Market – Clinical Pipeline by Company, 2011
Figure 38: Market Forecasting Model

Vertex Pharmaceuticals Inc.
PTC Therapeutics, Inc:
Mpex Pharmaceuticals, Inc.
Insmed Incorporated
Aradigm Corporation
GlaxoSmithKline plc
Actelion Ltd.
Parion Sciences, Inc
Chiesi Farmaceutici SpA.

Customers who bought this item also bought

• Will the Approval of New Agents Redefine the Cystic Fibrosis Market?
• Medical Nutrition - A Global Market Overview
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• Disinfectants - Global Strategic Business Report
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Cord Blood Stem Cells – A Global Market Overview
• The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures